NexGel, Inc. (NXGL)

NexGel, Inc.'s stock price has experienced significant volatility. As of March 24, 2026, the share price was $0.68, representing a substantial decline from $3.03 per share on March 25, 2025. In March 2026, NexGel announced an agreement to license and acquire regenerative biomaterial products, expected to triple revenue and contribute to immediate profitability. The company rescheduled its Fourth Quarter and Full Year 2025 financial results conference call to April 8th, 2026, to provide an update on the transaction with Celularity. In February 2026, NexGel announced it expected to receive $16.666 million in funding and priced $1,797,381 senior secured convertible notes for an acquisition, and a new major risk related to market cap size was noted. Full year 2025 earnings were released in April 2026, reporting a loss per share of $0.38, with revenue rising to $11.4 million, up 31.5% from 2024, driven by branded consumer products; however, the company acknowledged substantial doubt about its ability to continue as a going concern without additional capital. Historically, NXGL shares have moved lower in the immediate aftermath of earnings reports but have moved higher heading into earnings.

NexGel anticipates seasonal improvements in consumer product sales, particularly leading into the holiday seasons (Q3 and Q4), suggesting a degree of seasonality in the demand for its consumer-facing hydrogel products.

NexGel, Inc. is a biotechnology company specializing in advanced hydrogels for healthcare and consumer markets, operating within the Health Care sector. Headquartered in Langhorne, Pennsylvania, NexGel has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels. NexGel's business model is diversified, generating revenue from branded OTC products, private label solutions, and CDMO services. Its hydrogel technology is utilized in products for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. Major products and brands include SilverSeal®, MEDAGEL®, Turfguard®, Kenkoderm®, and Silly George®, and the company has formulated over 200 different hydrogel combinations.

NexGel, Inc. is based in Langhorne, Pennsylvania, where it operates an FDA-registered and ISO-certified cGMP manufacturing facility, R&D center, and converting operations. The company also has a CG Converting and Packaging, LLC (CGN) segment, a joint venture located in Granbury, Texas, which handles converting and packaging.

NexGel emphasizes the superior consumer experience and flexibility of its hydrogel products. The company's branded consumer products have shown strong sales growth, particularly within the Amazon Marketplace. The acquisition of the Silly George beauty brand in May 2024 significantly expanded its presence in global personal care and contributed to substantial revenue growth for the brand. NexGel also highlights positive reviews for products like SilverSeal, and its FDA-registered and ISO-certified facilities underscore its commitment to quality in manufacturing.

NexGel, Inc. has 27 institutional owners and shareholders holding a total of 603,897 shares, including Vanguard Group Inc, Morgan Stanley, and Geode Capital Management, Llc. As of November 2025, the majority of the company is held by the public, with insiders maintaining a strong stake. Institutional ownership stands at 7.4%, while insider ownership is 16.09%. Over the past six months, NexGel Inc insiders have engaged in 7 sales transactions and no purchases.